Language
English
German
^M
Dutch
Spanish
Title:
Human definitive hematopoietic specification from pluripotent stem cells is regulated by mesodermal expression of CDX4
Source:
Blood [0006-4971] Creamer, J P yr:2017
Basic
Sorry, no full text available...
Please use the document delivery service (see below)
Holding information
Holdings in library search engine
ALBERT
Document delivery
Request document via
Library/Bibliothek
Users interested in this article also expressed an interest in the following:
description
1.
Sturgeon, C.
"Human definitive hematopoiesis is regulated by CDX4 gene expression in early HPSC-derived mesoderm."
Experimental hematology
44.9 (2016).
description
2.
Sorour, A.
"Fine needle aspiration as a diagnostic technique in B-cell non-hodgkin lymphoma."
Experimental hematology
42.8 (2014).
description
3.
French, A.
"Human Induced Pluripotent Stem Cell-Derived B Lymphocytes Express sIgM and Can Be Generated via a Hemogenic Endothelium Intermediate."
Stem cells and development
24.9 (2015): 1082-95.
Select All
Clear All
Save Citations
Select Format
EndNote
RefWorks
Reference Manager
ProCite
Submit citation export
Advanced
Author
Other articles by this author? -- in
GeoRef
author:
Creamer, J P
Dege, Carissa
Ren, Qihao
Valentine, Mark C
Druley, Todd E
Sturgeon, Christopher M
last name
initials
Other articles by this author? -- in
Online Contents Geosciences
author:
Creamer, J P
Dege, Carissa
Ren, Qihao
Valentine, Mark C
Druley, Todd E
Sturgeon, Christopher M
last name
initials
Other articles by this author? -- using
Web of Science
author:
Creamer, J P
Dege, Carissa
Ren, Qihao
Valentine, Mark C
Druley, Todd E
Sturgeon, Christopher M
last name
initials
Web Search
Find related information in
a Web Search Engine
Excite
Google
HotBot
Ixquick
ZOO
Ask
Yahoo!
Bing
Naver
Search Terms:
Search for related information in
Google Scholar
Article Title
Author Name
Journal Title
Other Search
Search Terms:
A service provided by the
Library of the Wissenschaftspark Albert Einstein
, Potsdam, Germany.
© 2005 SFX by Ex Libris Inc.